{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:55:35Z","timestamp":1791172535654,"version":"4.1.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"DOI":"10.1093\/cid\/cit125","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:43:26Z","timestamp":1362098606000},"page":"1667-1674","source":"Crossref","is-referenced-by-count":64,"title":["Clinical Implications of HIV-1 Minority Variants"],"prefix":"10.1093","volume":"56","author":[{"given":"Jonathan Z.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Kuritzkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,2,27]]},"reference":[{"key":"key\n\t\t\t\t20170623052613_CIT125C1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/365671a0","article-title":"Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing","volume":"365","author":"Larder","year":"1993","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170623052613_CIT125C2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2353\/jmoldx.2006.050148","article-title":"Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D","volume":"8","author":"Church","year":"2006","journal-title":"J Mol Diagn"},{"key":"key\n\t\t\t\t20170623052613_CIT125C3","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":"Differential persistence of transmitted HIV-1 drug resistance mutation classes","volume":"203","author":"Jain","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/QAI.0b013e3182618f05","article-title":"Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients","volume":"61","author":"Yanik","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623052613_CIT125C5","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.2460924","article-title":"Fidelity of HIV-1 reverse transcriptase","volume":"242","author":"Preston","year":"1988","journal-title":"Science"},{"key":"key\n\t\t\t\t20170623052613_CIT125C6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170623052613_CIT125C7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"key\n\t\t\t\t20170623052613_CIT125C8","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.01010-10","article-title":"Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model","volume":"84","author":"Gadhamsetty","year":"2010","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jviromet.2007.06.012","article-title":"Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations","volume":"146","author":"Paredes","year":"2007","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20170623052613_CIT125C10","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1371\/journal.pone.0000638","article-title":"Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations","volume":"2","author":"Johnson","year":"2007","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jviromet.2009.11.025","article-title":"Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design","volume":"164","author":"Boltz","year":"2010","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20170623052613_CIT125C12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/JCM.36.2.569-572.1998","article-title":"Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine","volume":"36","author":"Edelstein","year":"1998","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C13","doi-asserted-by":"crossref","first-page":"e49602","DOI":"10.1371\/journal.pone.0049602","article-title":"Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism","volume":"7","author":"Archer","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(99)80008-7","article-title":"Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial","volume":"354","author":"Guay","year":"1999","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170623052613_CIT125C15","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/00002030-200110190-00006","article-title":"Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)","volume":"15","author":"Eshleman","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00126334-200402010-00004","article-title":"Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012)","volume":"35","author":"Eshleman","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623052613_CIT125C17","doi-asserted-by":"crossref","first-page":"F111","DOI":"10.1097\/00002030-200007280-00001","article-title":"Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission","volume":"14","author":"Jackson","year":"2000","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":"Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated","volume":"192","author":"Johnson","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.qai.0000221686.67810.20","article-title":"Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D","volume":"42","author":"Flys","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623052613_CIT125C20","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/AAC.01672-08","article-title":"Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR","volume":"53","author":"Hauser","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623052613_CIT125C21","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1128\/JCM.02062-09","article-title":"Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay","volume":"48","author":"Wagner","year":"2010","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3851\/IMP1698","article-title":"Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis","volume":"16","author":"Pilger","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170623052613_CIT125C23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/01.aids.0000222071.60620.1d","article-title":"Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission","volume":"20","author":"Loubser","year":"2006","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C24","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1073\/pnas.0602033103","article-title":"Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission","volume":"103","author":"Palmer","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20170623052613_CIT125C25","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/QAD.0b013e3283492180","article-title":"HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine","volume":"25","author":"Hunt","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1086\/430742","article-title":"Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012","volume":"192","author":"Flys","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C27","doi-asserted-by":"crossref","first-page":"e20357","DOI":"10.1371\/journal.pone.0020357","article-title":"Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis","volume":"6","author":"Hauser","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.qai.0000167154.37357.f9","article-title":"Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies","volume":"39","author":"Muro","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623052613_CIT125C29","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa0906626","article-title":"Antiretroviral therapies in women after single-dose nevirapine exposure","volume":"363","author":"Lockman","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623052613_CIT125C30","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.1105688108","article-title":"Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine","volume":"108","author":"Boltz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20170623052613_CIT125C31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1086\/596486","article-title":"Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"48","author":"Coovadia","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/aid.2009.0082","article-title":"Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance","volume":"26","author":"Rowley","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20170623052613_CIT125C33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jcv.2010.03.017","article-title":"Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART","volume":"48","author":"MacLeod","year":"2010","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/QAI.0b013e3182515730","article-title":"Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment","volume":"60","author":"Lehman","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623052613_CIT125C35","doi-asserted-by":"crossref","first-page":"e1000172","DOI":"10.1371\/journal.pmed.1000172","article-title":"Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial","volume":"6","author":"McIntyre","year":"2009","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170623052613_CIT125C36","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(07)61605-5","article-title":"Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial","volume":"370","author":"Chi","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170623052613_CIT125C37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/aid.2009.0088","article-title":"Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention","volume":"25","author":"Chi","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20170623052613_CIT125C38","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1086\/650745","article-title":"Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine","volume":"50","author":"Lallemant","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3851\/IMP1946","article-title":"Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women","volume":"17","author":"Palmer","year":"2012","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170623052613_CIT125C40","doi-asserted-by":"crossref","first-page":"e32055","DOI":"10.1371\/journal.pone.0032055","article-title":"Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission","volume":"7","author":"Hauser","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C41","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jis282","article-title":"Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine","volume":"205","author":"Micek","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir798","article-title":"A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine","volume":"54","author":"Van Dyke","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcv.2009.03.002","article-title":"Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure","volume":"45","author":"Balduin","year":"2009","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/QAI.0b013e3181ba11e8","article-title":"Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy","volume":"52","author":"Geretti","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623052613_CIT125C45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0b013e3283427dcb","article-title":"Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy","volume":"25","author":"Goodman","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1086\/650001","article-title":"Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome","volume":"50","author":"Jakobsen","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C47","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy","volume":"5","author":"Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170623052613_CIT125C48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/595703","article-title":"Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients","volume":"48","author":"Metzner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2010.10.001","article-title":"Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients","volume":"50","author":"Metzner","year":"2011","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C50","first-page":"662","article-title":"Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure","volume":"201","author":"Paredes","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C51","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/QAD.0b013e3283034953","article-title":"Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy","volume":"22","author":"Peuchant","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C52","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes","volume":"199","author":"Simen","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3851\/IMP1687","article-title":"HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis","volume":"16","author":"Buckton","year":"2010","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170623052613_CIT125C54","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1468-1293.2010.00882.x","article-title":"Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance","volume":"12","author":"Buckton","year":"2010","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20170623052613_CIT125C55","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170623052613_CIT125C56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0b013e32834e9d7d","article-title":"Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure","volume":"26","author":"Li","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C57","article-title":"Antiretroviral drug-resistant minority variants are significantly associated with first-line treatment failure in antiretroviral drug-naive patients","author":"Papathanasopoulos"},{"key":"key\n\t\t\t\t20170623052613_CIT125C58","article-title":"The risk of virologic failure associated with low frequency nevirapine-resistant variants in women initiating nevirapine-containing ART varies depending on the history of exposure to sd-Nevirapine: OCTANE\/ACTG 5208","author":"Boltz"},{"key":"key\n\t\t\t\t20170623052613_CIT125C59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.diagmicrobio.2011.09.020","article-title":"Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing","volume":"72","author":"Garcia-Gonzalez","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C60","doi-asserted-by":"crossref","first-page":"e21655","DOI":"10.1371\/journal.pone.0021655","article-title":"Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure","volume":"6","author":"Delobel","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C61","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/589867","article-title":"Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy","volume":"47","author":"Hare","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C62","doi-asserted-by":"crossref","first-page":"e6079","DOI":"10.1371\/journal.pone.0006079","article-title":"Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use","volume":"4","author":"Le","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C63","first-page":"672","article-title":"Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients","volume":"201","author":"Halvas","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00126334-200501010-00007","article-title":"Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine","volume":"38","author":"Lecossier","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623052613_CIT125C65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/QAI.0b013e3181bca669","article-title":"Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors","volume":"52","author":"Varghese","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170623052613_CIT125C66","doi-asserted-by":"crossref","first-page":"e19461","DOI":"10.1371\/journal.pone.0019461","article-title":"Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects","volume":"6","author":"Codoner","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C67","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/428096","article-title":"Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection","volume":"191","author":"Moyle","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C68","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1097\/QAD.0b013e3283498305","article-title":"Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing","volume":"25","author":"Raymond","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C69","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir","volume":"80","author":"Westby","year":"2006","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C70","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/QAD.0b013e32832b4399","article-title":"Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing","volume":"23","author":"Archer","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C71","doi-asserted-by":"crossref","first-page":"e5683","DOI":"10.1371\/journal.pone.0005683","article-title":"Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo","volume":"4","author":"Tsibris","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C72","doi-asserted-by":"crossref","first-page":"e1001022","DOI":"10.1371\/journal.pcbi.1001022","article-title":"The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time\u2014an ultra-deep approach","volume":"6","author":"Archer","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C73","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.antiviral.2011.10.003","article-title":"Rescue of HIV-1 long-time archived X4 strains to escape maraviroc","volume":"92","author":"Baatz","year":"2011","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20170623052613_CIT125C74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jiq030","article-title":"Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients","volume":"203","author":"Swenson","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C75","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/cir493","article-title":"Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc","volume":"53","author":"Swenson","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C76","doi-asserted-by":"crossref","first-page":"e46334","DOI":"10.1371\/journal.pone.0046334","article-title":"A Genotypic Test for HIV-1 tropism combining Sanger sequencing with Ultradeep sequencing predicts virologic response in treatment-experienced patients","volume":"7","author":"Kagan","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C77","doi-asserted-by":"crossref","first-page":"e10952","DOI":"10.1371\/journal.pone.0010952","article-title":"Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study","volume":"5","author":"Lataillade","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C78","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3851\/IMP1461","article-title":"Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina","volume":"14","author":"Vignoles","year":"2009","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170623052613_CIT125C79","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3201\/eid1710.110592","article-title":"Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant","volume":"17","author":"Bansal","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C80","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1086\/651136","article-title":"Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy","volume":"201","author":"Metzner","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C81","doi-asserted-by":"crossref","first-page":"8359","DOI":"10.1128\/JVI.02582-10","article-title":"Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants","volume":"85","author":"Gianella","year":"2011","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C82","doi-asserted-by":"crossref","first-page":"e28952","DOI":"10.1371\/journal.pone.0028952","article-title":"Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection","volume":"6","author":"Stekler","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/aid.2010.0077","article-title":"Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing","volume":"27","author":"D'Aquila","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20170623052613_CIT125C84","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.antiviral.2010.09.016","article-title":"Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure","volume":"88","author":"Codoner","year":"2010","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20170623052613_CIT125C86","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e3283367796","article-title":"High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors","volume":"24","author":"Charpentier","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C87","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1128\/AAC.01492-10","article-title":"Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment","volume":"55","author":"Liu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623052613_CIT125C88","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1128\/AAC.01720-09","article-title":"Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors","volume":"54","author":"Ceccherini-Silberstein","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623052613_CIT125C89","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/QAD.0b013e32834b34de","article-title":"Switching between raltegravir resistance pathways analyzed by deep sequencing","volume":"25","author":"Mukherjee","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C90","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jir821","article-title":"Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing","volume":"205","author":"Armenia","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C91","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-1293.2012.01039.x","article-title":"Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens","volume":"14","author":"Nguyen","year":"2013","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20170623052613_CIT125C92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/aid.2009.0189","article-title":"Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir\/emtricitabine in antiretroviral-naive HIV-infected patients","volume":"26","author":"Ross","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20170623052613_CIT125C93","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1097\/01.aids.0000189878.97480.ed","article-title":"Detection of minor populations of drug-resistant HIV-1 in acute seroconverters","volume":"19","author":"Metzner","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170623052613_CIT125C94","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3851\/IMP1812","article-title":"Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy","volume":"16","author":"McKinnon","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170623052613_CIT125C95","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1128\/JVI.06541-11","article-title":"Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen","volume":"86","author":"Fisher","year":"2012","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C96","doi-asserted-by":"crossref","first-page":"e30118","DOI":"10.1371\/journal.pone.0030118","article-title":"Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing","volume":"7","author":"Lataillade","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C97","article-title":"Resistance to protease inhibitors","author":"van Maarseveen","year":"2006"},{"key":"key\n\t\t\t\t20170623052613_CIT125C98","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170623052613_CIT125C99","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1086\/386291","article-title":"Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens","volume":"189","author":"Colonno","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052613_CIT125C100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jviromet.2011.08.020","article-title":"Human immunodeficiency virus type 1 drug resistance testing: evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit","volume":"178","author":"Stelzl","year":"2011","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20170623052613_CIT125C101","doi-asserted-by":"crossref","first-page":"e36494","DOI":"10.1371\/journal.pone.0036494","article-title":"Low-cost ultra-wide genotyping using Roche\/454 pyrosequencing for surveillance of HIV drug resistance","volume":"7","author":"Dudley","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623052613_CIT125C102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jviromet.2011.04.023","article-title":"HIV-1 nucleotide mixture detection in the virco((R))TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing","volume":"175","author":"De Wolf","year":"2011","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20170623052613_CIT125C103","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1128\/JCM.02652-12","article-title":"Evaluation of a Benchtop HIV ultradeep pyrosequencing drug-resistance assay in the clinical laboratory","volume":"51","author":"Avidor","year":"2013","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623052613_CIT125C104","volume-title":"Novel HIV-1 resistance and tropism testing","author":"Li","year":"2012"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/56\/11\/1667\/17851071\/cit125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:27:55Z","timestamp":1595464075000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cit125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,27]]},"references-count":104,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,2,27]]},"published-print":{"date-parts":[[2013,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit125","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,27]]}}}